Dr. Caussade holds a Doctorate in Pharmacy and a Ph.D. in Biochemistry. Prior to founding ANS Biotech, he gained more than 20 years of research and leadership experience in the drug discovery and preclinical development of novel therapeutics in the R&D divisions of pharmaceutical (UPSA, Bristol Myers Squibb) and biotech (CEREP) companies. Dr. Caussade successfully led several R&D projects focused on the characterization of novel chemical matter for the treatment of inflammatory pain and neuropathic pain. He is the co-author of more than 20 scientific papers and over 30 published abstracts.
Dr. Diop earned his Ph.D. in Molecular and Cellular Biology and has held senior leadership positions within various pharmaceutical companies (Jouveinal, Parke-Davis, Pfizer) where he actively contributed to drug development projects in digestive motility and visceral pain. In particular, he led R&D programs designed to evaluate the efficacy of new compounds for the treatment of IBS and IBD. He has co-authored 6 patents, 41 research articles, 3 book chapters and over 70 published abstracts.
Dr. Darbaky earned his Ph.D. in Neuroscience and spent the first years of his career at Sanofi-aventis, where he developed innovative models of chemo-induced neuropathies in rodents. He then moved to Neorphys and led the biology and pharmacology research activities focused on the discovery of novel analgesics. He spent 13 years at ANS Biotech as Head of the in vivo Pharmacology Laboratory where he managed fee-for-services activities and R&D projects in pain pharmacology. As Chief Business Officer, Yassine is now in charge of the business activities of the company.